10:46 AM EDT, 06/17/2025 (MT Newswires) -- BioAge Labs ( BIOA ) said Tuesday it launched an initiative to profile more than 17,000 samples from Norway's HUNT Biobank to expand its drug discovery platform focused on aging and chronic disease.

In partnership with Norwegian diagnostics firm Age Labs, BioAge ( BIOA ) will analyze biological data collected over decades from more than 6,000 individuals. The study will focus on aging trajectories linked to cardiometabolic disease, dementia, and other chronic conditions, using Standard BioTools' SomaScan assay to measure thousands of proteins per sample.

BioAge ( BIOA ) said it will apply machine learning to uncover molecular signatures tied to disease onset and progression, and holds exclusive drug discovery rights to the resulting data.

Price: 4.39, Change: +0.01, Percent Change: +0.14